Alternative monitoring of argatroban using plasma-diluted thrombin time

Annals of Pharmacotherapy

Volumn 47, Issue 4, 2013, Pages

  Wanat, Matthew A ^a   Hart, Sara R ^b   Putney, David ^b   Liebl, Michael G ^b   Chandler, Wayne ^c  

^a UNIVERSITY OF HOUSTON   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c Division of Vascular Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; FUROSEMIDE; LEVOTHYROXINE; MIDODRINE; OMEPRAZOLE; WARFARIN;

ABDOMINAL DISCOMFORT; AGED; ARTICLE; CASE REPORT; CHRONIC KIDNEY DISEASE; COLON INTUSSUSCEPTION; COLONOSCOPY; COLOSTOMY; DRUG DOSE REDUCTION; DRUG MONITORING; GASTROESOPHAGEAL REFLUX; GOUT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART PALPITATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOTENSION; HYPOTHYROIDISM; LIVER DYSFUNCTION; MALE; OBESITY; ORTHOSTATIC HYPOTENSION; PACEMAKER; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; TACHYCARDIA; THROMBIN TIME;

EID: 84876252367     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R644     Document Type: Article

References (9)

1. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007;35:1165-76. doi: 10.1097/01.CCM.0000259538.02375.A5
2. Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy 2007;27:564-87. doi: 10.1592/phco.27.4.564
3. Koster A, Fischer K, Harder S, Mertzlufft F. The direct thrombin inhibitor argatroban: a review of use in patients in patients with and without HIT. Biologics Targets Ther 2007;1:105-12. doi: 10.2147/BTT.S
4. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e495S-530S. doi: 10.1378/chest.11-2303
5. Wenzel C, Stoiser B, Locker GJ, et al. Frequent development of lupus anticoagulants in critically ill patient treated under intensive care conditions. Crit Care Med 2002;30:763-70. doi: 10.1097/00003246-200204000-00007
6. Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 2007;98:234-42. doi: 10.1160/TH06-10-0607
7. Smythe MA, Koerber JM, Forsyth LL, et al. Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients. Pharmacotherapy 2009;29:1073-81. doi: 10.1592/phco.29.9.1073
8. Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol 2012;137:572-4. doi: 10.1309/AJCPAU7OQM0SRPZQ
9. Mack DR, Kim JJ. Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation. Ann Pharmacother 2012;46:1105-10. doi: 10.1345/aph.1R057